… Ian Bruce and David Isenberg, allowed intense discussions of the criteria deficiencies.
Cases that were misclassified by the rule were used to stimulate discussions regarding how the …

Background Anifrolumab, a human monoclonal antibody to type I interferon receptor subunit
1 investigated for the treatment of systemic lupus erythematosus (SLE), did not have a …

The principle of treating-to-target has been successfully applied to many diseases outside
rheumatology and more recently to rheumatoid arthritis. Identifying appropriate therapeutic …

The major histocompatibility complex (MHC) on chromosome 6 is associated with susceptibility
to more common diseases than any other region of the human genome, including almost …

Background and aims We studied damage accrual and factors determining development
and progression of damage in an international cohort of systemic lupus erythematosus (SLE) …

Objective Because women with systemic lupus erythematosus (SLE) are 5–8 times more
likely to develop coronary heart disease (CHD) than are women in the general population, we …

Objective. To determine nephritis outcomes in a prospective multi-ethnic/racial SLE
inception cohort. Methods. Patients in the Systemic Lupus International Collaborating Clinics …

Background Patients with systemic lupus erythematosus have substantial unmet medical
need. Baricitinib is an oral selective Janus kinase (JAK)1 and JAK2 inhibitor that we …

Objective To develop recommendations for cardiovascular risk (CVR) management in gout,
vasculitis, systemic sclerosis (SSc), myositis, mixed connective tissue disease (MCTD), …

Psoriatic arthritis (PsA) is an inflammatory joint disease that is distinct from other chronic
arthritides and which is frequently accompanied by psoriasis vulgaris (PsV) and seronegativity …